ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1786

SEV-101, A Regenerative Exosome Therapeutic for the Treatment of Osteoarthritis

Beth Lindborg1, Amanda Vegoe2, Michael Williams1, Parthasarathy Rangarajan3, Marc Tompkins4, Sabarinathan Ramachandran5 and Timothy O'Brien6, 1Sarcio, Inc., St. Paul, 2Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, St. Paul, 3Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, 4Department of Orthopedic Surgery, University of Minnesota, Sarcio, Inc., Minneapolis, 5Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, MN, 6Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, Minneapolis

Meeting: ACR Convergence 2025

Keywords: Animal Model, cartilage, Collagen, Orthopedics, Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1780–1808) Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Osteoarthritis (OA) is a chronic, debilitating joint disease affecting 595 million people worldwide, including over 32 million in the United States. It is characterized by progressive degeneration of articular cartilage, most commonly in the knees, hips, and hands. Risk increases with age, joint overuse, and obesity. Despite an annual economic burden of $550 billion in the US, no FDA approved disease-modifying osteoarthritis drugs (DMOADs) are currently available. In this study, we evaluate the therapeutic potential of SEV-101, a novel exosome-based treatment, to promote hyaline cartilage regeneration in weight-bearing regions of the knee in a rat model of OA.

Methods: SEV-101 is a novel exosome therapeutic isolated from induced pluripotent stem cell (iPSC)-derived cartilage tissue. To evaluate the efficacy of SEV-101 in regenerating hyaline cartilage, the rat monosodium iodoacetate (MIA) model of OA was utilized. On Day 1, animals received a unilateral intra-articular injection of MIA in the knee (femorotibial) joint. Treatment began on Day 4 and was administered once per week for 10 weeks. Animals were randomized into four treatment groups (7 males, 7 females per group) and one naïve control group (5 males, 5 females). SEV-101 was dosed at 2.2 × 10¹¹ exosomes. Phosphate-buffered saline served as a vehicle control. FGF-18 was used as a positive control as it has been shown to promote cartilage regeneration. A standard-of-care positive control for pain included intra-articular triamcinolone and oral tramadol. In-life assessments included safety monitoring and Dynamic Weight Bearing (DWB) analysis. Animals were sacrificed on Day 72, and joints underwent histological evaluation, including quantitative analysis of hyaline cartilage regeneration in the medial joint compartment. Rigorous criteria included presence of tidemark and bone resorption, in addition to other measurements that ensured that the cartilage being measured was new, good quality hyaline cartilage.

Results: No safety signals were observed in SEV-101 treated rats. SEV-101 treated male rats showed a statistically significant increase in regeneration of hyaline articular cartilage in weight-bearing regions of the knee joint (designated as “good quality hyaline cartilage”) compared to all other treatment groups. In addition, SEV-101 treated male rats showed more intact meniscus structure and more Type 2 Collagen immunohistochemical staining compared to vehicle controls. There was no significant difference in DWB vehicle controls and SEV-101 treated animals.

Conclusion: SEV-101 promoted the regeneration of new hyaline cartilage rather than merely preserving existing cartilage. Additionally, SEV-101-treated animals exhibited improved meniscal integrity and increased Type II Collagen staining relative to vehicle controls. These findings support SEV-101’s capacity to regenerate cartilage in weight-bearing regions of the joint and to confer structural protection, reducing the risk of further degeneration. Collectively, these data strongly support the continued development of SEV-101 as a DMOAD.

Supporting image 1Figure 1. Good Quality Hyaline Cartilage Repair Width in the Medial (weight bearing) Knee Joint. Toluidine Blue Stained Histological sections of knee joints in male animals were assessed using the following criteria to ensure that regeneration, and not preservation was being measured: 1) the tidemark and corresponding bone/calcified cartilage had evidence of resorption, 2) the presence of proteoglycan (any degree of blue pigment) and/or chondrocytes within the intact pre-existing cartilage matrix, 3) had evidence of normal chondrocyte arrangement/maturation (does not have obvious features of fibrocartilage, such as elongate cellular morphology or streaming).

Supporting image 2Figure 2. Histopathology of the medial compartment of male right stifle (knee) joints stained with toluidine blue. Vehicle control animals showed extensive loss of articular cartilage (red bracket delineates affected areas) with minimal regeneration of articular cartilage evident. SEV-101 treated animals showed prominent regions of articular hyaline cartilage regeneration (green bracket delineates this region and green arrows indicate chondrogenic clusters forming hyaline cartilage).


Disclosures: B. Lindborg: Sarcio, Inc., 12,, 4, 8, 10, 11; A. Vegoe: Sarcio, Inc., 12,, 4, 8, 10, 11; M. Williams: Sarcio, Inc., 12,, 4, 8, 11; P. Rangarajan: Sarcio, Inc., 5; M. Tompkins: Sarcio, Inc., 12,, 4, 11; S. Ramachandran: Sarcio Inc, 5; T. O'Brien: Sarcio, Inc., 12,, 4, 8, 10, 11.

To cite this abstract in AMA style:

Lindborg B, Vegoe A, Williams M, Rangarajan P, Tompkins M, Ramachandran S, O'Brien T. SEV-101, A Regenerative Exosome Therapeutic for the Treatment of Osteoarthritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/sev-101-a-regenerative-exosome-therapeutic-for-the-treatment-of-osteoarthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sev-101-a-regenerative-exosome-therapeutic-for-the-treatment-of-osteoarthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology